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Abstract
The prevalence of opioid abuse in the United States has been steadily increasing over the last several years among
many major demographics, including pregnant women. Rise in prenatal opioid abuse has resulted in subsequent
escalation of neonatal abstinence syndrome incidence, prompting the US Congress to pass the Protecting Our
Infants Act of 2015. This act specifically calls for a critical review of current treatment options for prenatal opioid
abuse which may ultimately lead to the development of better therapies and a decreased incidence of neonatal
abstinence syndrome. Currently, the American College of Obstetricians and Gynecologists recommends methadone,
buprenorphine, or buprenorphine/naloxone in the treatment of prenatal opioid abuse. In this review, each
maintenance therapy treatment option is discussed and compared revealing inconsistencies in postpartum
retention rates, effects on fetal development, and availability to patients due to restrictions in health care coverage.
Although each of these treatment options reduces opioid abuse and potential negative outcomes for the fetus, the
shortcomings of these drugs highlight the overarching need for an improved standard of care. Drug developers
and lawmakers should consider that affordability, coverage by health insurance, and success in retention rates
substantially impacts the decision of the patient and healthcare provider regarding utilization of a particular opioid
maintenance therapy.
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Background
Opioid use in the United States has been steadily in-
creasing since 2000 [1]. Between 2007 and 2013 alone,
the number of users increased from 373,000 to 681,000
[1]. In 2014, 49.2% (18,893) of all drug abuse deaths in
the United States were due to opioid abuse [2]. As opi-
oid abuse continues to increase in the United States, one
specific population at risk is pregnant women and their
unborn fetuses. Among women that abuse opioids, early
signs of pregnancy such as nausea, vomiting, and cramp-
ing are often confused with opioid withdrawal symptoms
which leads to prolonged and sometime increased use of
opioids. Because of the risks associated with these with-
drawal symptoms, it is currently recommended for
women addicted to opioids while pregnant to enter a
treatment program consisting of methadone or bupre-
norphine [3].
Increases in drug use during pregnancy have resulted
in an escalation in the occurrence of Neonatal Abstinence
Syndrome (NAS), a drug-withdrawal syndrome that mani-
fests after opioid penetration of the placental barrier
resulting in-utero exposure [4]. The most dramatic in-
crease was observed from 2009 to 2012, where NAS inci-
dence increased nationally from 34 to 58 per 1,000
hospital births [5].
In addition to NAS, several other disorders and mor-
bidities of neonates are associated with opioid use dur-
ing pregnancy [6, 7]. For instance, infants who were
subjected to opioids in utero have a higher incidence of
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stillbirth [6, 8, 9]. Moreover, use of particular prescrip-
tion opioids during pregnancy is associated with con-
genital heart defects [10, 11]. The neonates who survive
childbirth often experience a reduced growth rate
compared to those whose mothers did not abuse opioids
[6, 8, 9]. Secondary effects of opioid abuse often ad-
versely affect the fetus as well. For example, women
dependent on opioids have a higher incidence of anxiety
and depression which may lead to aberrant neurological
development of the fetus [6, 12, 13].
In response to the rise in prenatal opioid abuse and
NAS, US Congress passed the Protecting Our Infants
Act of 2015. This act requires the Department of Health
and Human Services to evaluate and make recommen-
dations on available treatments for women who continue
to abuse opioids during their pregnancies, as well as
identify any potential barriers of those existing treat-
ments [14]. Currently, there are three drugs being used
to treat general opioid dependence as well as opioid addic-
tion among pregnant women; methadone, buprenorphine,
and a combination drug containing buprenorphine/
naloxone (B/N) [15]. The College of Obstetricians and
Gynecologists recommends referral for opioid-assisted
therapy with methadone, but also recognizes evidence in
support of buprenorphine and B/N treatment creating a
lack of consensus for a standard of care [16].
In an attempt to address the Protecting Our Infants
Act of 2015, this paper will review strengths, weak-
nesses, and inconsistencies of the currently available
treatment options for prenatal opioid abuse and address
potential contributors to gaps in treatment research.
Review of prenatal opioid abuse treatment
options
Methadone
Methadone is a synthetic opioid that has been com-
monly used for the treatment of opioid dependence and
is primarily administered orally, sometimes intraven-
ously, and rarely subcutaneously, spinally or through
rectal routes. Structurally, methadone possesses a chiral
carbon, and typically a racemic mixture of both the
D- and L- isomers comprise the therapeutic form of
this drug [17]. Either isomer binds to the μ-opioid re-
ceptors (acting as an agonist) and blocks the N-methyl-D-
aspartate (NMDA) receptors (acting as an antagonist)
thereby preventing monoaminergic reuptake transporters
[17, 18]. Because methadone has both agonist and antag-
onist effects this drug leads to decreased tolerance com-
pared to other opioids [17].
Methadone is a widely accepted treatment for opioid
dependence among healthcare providers. Since the
1960s, methadone has been recommended as the standard
of care showing no serious long-term side effects [19].
Methadone is well absorbed in the gastrointestinal (GI)
tract and holds a long half-life of 25–52 h contributing to
a low frequency of administration [17]. Methadone also
has a stronger antagonist ability when binding to the
NMDA receptors than the alternative therapeutics.
Methadone does have some serious drawbacks when
considering administration. Because of opioid nature of
this therapeutic and the longer half-life associated with
methadone, there is potential for methadone overdose
[20]. Moreover, methadone has been shown to cause
harmful respiratory depression, constipation, and poten-
tial addiction and convulsions if toxic amounts are
administered [17]. The US black box warning for metha-
done indicates that life-threatening QT prolongation
and serious arrhythmias have occurred in patients using
methadone. This warning urges patients to monitor for
ECG changes during the start of treatment or after in-
creasing the dose. In addition, utilization of methadone
along with other central nervous system depressants
such as benzodiazepines and alcohol can be fatal [21].
Furthermore, a fetus exposed to methadone is at risk for
adverse perinatal outcomes such as decreased birth-
weight and NAS [22]. Unlike the other therapies
discussed below, additional regulations regarding pre-
scription methadone limit patient accessibility to this
drug [23]. For instance, methadone is only available from
healthcare providers that have been registered by the
Drug Enforcement Agency as a substance abuse treat-
ment facility. In these cases, the methadone must be
administered by this registered facility. Moreover, metha-
done is not covered by Medicaid in many states, produ-
cing a financial burden that may further reduce
accessibility of this drug to patients [23].
Buprenorphine
Buprenorphine is a long-acting, potent phenanthrene
derivative. This drug is often referred to as a mixed
agonist–antagonist because buprenorphine acts as a par-
tial agonist to μ receptors, and an antagonist to the δ
and κ receptors, lessening the euphoria brought about
by opioid abuse [17]. Buprenorphine is administered
sublingually in order to avoid first-pass absorption. In
addition to this prolonged absorption, buprenorphine
also has a slow dissociation rate from μ receptors, which
allows for a longer duration of action [17]. In addition,
buprenorphine can also be administered as a subdermal
implant
Pregnant women who use buprenorphine to treat opi-
oid addiction have children with higher birth weights,
larger head circumference, and fewer defects compared
to those who use methadone [24]. Moreover, use of
buprenorphine over methadone lowers the risk for pre-
term birth in pregnant women addicted to opiates [24].
In a retrospective cohort study that compared buprenor-
phine with methadone, mothers who used buprenorphine
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rather than methadone gave birth to larger infants
and had longer gestation periods [19]. The infants of
the buprenorphine group also required significantly
less and shorter treatments for neonatal abstinence
syndrome [19].
Buprenorphine, like methadone, has several disadvan-
tages for mothers and infants. Both of these drugs may
increase the risk of serious respiratory depression and
death. This risk rises when buprenorphine is used in
conjunction with benzodiazepines (psychoactive drugs
used to treat anxiety), alcohol, patients who suffer from
panic disorders, as well as central nervous system (CNS)
depressants such as sedatives or antipsychotics [17]. An-
other drawback to using buprenorphine is that there is a
lower retention rate for opioid dependence in patients
who use buprenorphine (46%) versus methadone (74%)
[24]. Moreover, buprenorphine-containing products are
often abused, due to the ability of this drug to give a per-
son a sense of euphoria when used in large quantities
sublingually [25]. The potential for misuse of buprenor-
phine has led to increased illegal sales, sharing, and trad-
ing for other substances [25].
Buprenorphine/naloxone (B/N)
The combination of B/N is used to treat opioid addic-
tion and prevent buprenorphine abuse. As previously
mentioned, buprenorphine is a partial agonist for the μ-
opioid receptor. Buprenorphine’s agonist-binding activity
blocks the receptor site, preventing opioids from attach-
ing. Naloxone is a pure μ-opioid antagonist that not only
binds to receptor sites to block opioid action, but can
also reverse side effects of opioid use. Naloxone removes
opioids from μ-receptors in the brain, which brings the
individual into a state of withdrawal. The liver removes
naloxone when taken orally during first-pass metabol-
ism, therefore preventing transport to the brain. Because
buprenorphine only partially binds the μ opioid receptor,
the effects of this drug do not increase linearly with the
dose and patients experience a “ceiling effect” as the ac-
tivity of this drug plateaus above a certain concentration
unlike the other opioid treatments. This ‘ceiling effect’
makes buprenorphine a safer choice than other full ago-
nists at higher doses [26].
Of the current therapies to treat opioid addiction, per-
haps the combination of B/N has the greatest potential.
Because the pure opioid antagonist, naloxone, is in-
cluded along with buprenorphine, there is minimal street
value to this drug, and little likelihood for abuse. The
withdrawal state experienced by the patient upon injec-
tion or intranasal administration further opposes misuse
[25]. Generally, the retention rate of B/N increases with
the dose of this treatment, and this therapy is associated
with a high rate of completion (30–32 mg had a 24-week
treatment plan completion rate of 60%) [27]. Patients
taking B/N also exhibit a reduced relapse rate. For in-
stance, approximately 55–80% of patients who use
methadone relapse, and buprenorphine is found to
have a 50% rate of relapse [28, 29]. In contrast, there
are no relapses found in 79% of those treated with
buprenorphine/naloxone [30]. Therefore, treating indi-
viduals with B/N significantly decreases the chance of
opiate relapse [31]. Currently, women who become
pregnant while taking B/N therapy are advised to dis-
continue use of naloxone, but maintain the buprenor-
phine regimen [16]. Because insufficient evidence
exists regarding B/N utilization in pregnant women,
there are potential risks associated with any undiscov-
ered side effects or unfavorable outcomes.
The main shortcoming of utilizing B/N to treat opioid
addiction is the cost. B/N is newer compared to other
treatment methods for opioid abuse, making it more ex-
pensive than some of the other options while being
manufactured under patent. Although the patent for B/
N tablets expired in 2009 (making these currently avail-
able as a generic), Reckitt Benckiser introduced a new
dosage form (a sublingual film strip) to the market
which was filed under a new patent. Although other dos-
age forms of B/N exist, all remain more expensive in
comparison to Methadone and Buprenorphine [31]. Be-
cause studies showed fewer adverse effects on the fetus
when treated with B/N as compared to methadone and
buprenorphine for opioid-dependence during pregnancy,
this may be a superior treatment option [15]. However,
cost, lack of coverage by health insurance, and an un-
willingness to deviate from conventional treatments by
some healthcare providers may impair the utilization of
this drug.
Discussion
Because of the inherent vulnerability of the developing
fetus, obstetricians and neonatologists face many chal-
lenges associated with treating pregnant women who use
opiates. Moreover, the existing maintenance therapies
for opiate abuse have various shortcomings.
This review discusses three maintenance therapies for
prenatal opioid abuse: methadone, buprenorphine, and
B/N. Although methadone has been a standard of care
for opioid abuse since the 1960s, utilization of this drug
can have severe effects on an unborn fetus [19, 22].
Methadone is also not covered by Medicaid in several
states, which presents a significant barrier in availability
of this treatment option [23]. In contrast to methadone,
utilizing buprenorphine in treatment of prenatal opioid
abuse results in healthier babies born with higher birth
weights and lower treatment times for NAS [19]. How-
ever, buprenorphine may still cause negative side effects
in infants such as respiratory depression and has also
been observed to have a lower postpartum retention rate
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in opioid dependent patients than methadone [17, 24].
B/N appears to present an improved treatment option in
prenatal opioid abuse with 60% completion rate and de-
creased abuse likelihood due to lower street value [27].
However, the novelty of this treatment option limits its
availability to patients and any potential benefits associ-
ated with its implementation [31]. For instance, being a
newly developed drug, little evidence exists regarding
the potential unrecognized dangers of B/N treatment
during pregnancy. Future work should focus on deter-
mining whether the combinatorial B/N is safe to use
during pregnancy.
Women who use opiates are often advised by their
health care professionals to use contraception. These
discussions are recommended to begin during preg-
nancy, and long-term but reversible contraception is
often provided/prescribed after childbirth [16]. This is
especially important as women who use drugs have a
lower tendency to use planned (non-condom) contra-
ception [32].
The aforementioned variability across prenatal opioid
treatment effects and success may be accredited to
demographic differences, such as race, ethnicity, socio-
economic status, and education level, and how those
populations respond to accessible treatments. Research
lacks focus on the effectiveness of methadone, buprenor-
phine, and B/N regarding specific demographic groups.
The neglect of the impact of these demographic parame-
ters in research studies – and how these parameters in-
fluence treatment availability and retention – may be
contributing to the inadequate treatment success. Future
studies should pay close attention to key demographic
indicators, such as those mentioned above, that could
influence healthcare decisions based on patient income
or level of healthcare coverage.
Conclusions
As requested by the Protecting Our Infants Act of 2015,
information presented in this article identifies some of
the major gaps in prenatal opioid abuse research such as
inconsistencies in treatment success, lack of availability
in treatment options, and lack of a consensus on a
standard of care. Specifically, this article provides
considerations for the three most appropriate opioid
maintenance therapy options for pregnant women ac-
cording to the American College of Obstetricians and
Gynecologists. Although each treatment option presents
some benefits in reducing opioid abuse and negative
outcomes for the fetus, weaknesses and inconsistencies
of each present the overarching need for an improved
standard of care. To improve prenatal opioid abuse
therapy options, drug development must significantly
place focus on availability in terms of healthcare cover-
age and treatment costs, success in retention rates for
opioid-abusing patients postpartum, and minimizing
negative outcomes for the fetus and newborn regarding
the previously stated demographic groups. Future research
is therefore pertinent in addressing the aforementioned
gaps in order to combat the increasing prevalence of pre-
natal opioid abuse.
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